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ABSTRACT
Ramelteon is a tricyclic synthetic analog of 
melatonin that acts speciﬁcally on MT1 and 
MT2 melatonin receptors. Ramelteon’s half-
life is longer than that of melatonin, being 
metabolized in the body to four main meta- 
bolites, M-I, M-II, M-III, and M-IV. M-II has an 
afﬁnity to MT1 and MT2 of about one-tenth of 
the parent compound, but its concentration in 
the circulation exceeds that of ramelteon by 
more than an order of magnitude. Ramelteon 
is effective in decreasing latency to persistent 
sleep and increasing total sleep time in freely 
moving monkeys. A number of clinical stud-
ies have been undertaken to study the efﬁcacy 
of ramelteon in subjects with chronic insom-
nia. In almost all of these studies, ramelteon, 
in various doses of 4, 8, or 16 mg most com-
monly, significantly reduced sleep latency 
and increased sleep duration. Its primary 
action in sleep promotion is not a generalized 
gamma-aminobutyric (GABA)-ergic central ner-
vous system depression, but rather it acts as a 
melatonergic agonist in the suprachiasmatic 
nucleus (and at other central nervous sys-
tem sites), from where downstream processes, 
including GABA-ergic effects, are controlled via 
the hypothalamic sleep switch. Unlike other 
commonly prescribed hypnotic drugs, ramelt-
eon is not associated with next morning hang-
over effects or reductions in alertness, nor has 
it been shown to cause withdrawal symptoms. 
The adverse symptoms reported with ramelteon 
are mild. All long-term investigations that have 
been carried out support the conclusion that 
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ramelteon is a well tolerated and effective drug 
for the treatment of insomnia.
Keywords: hypnotic; insomnia; melatonin; 
ramelteon
INTRODUCTION
Melatonin, the major hormone secreted by 
the pineal gland, was ﬁrst identiﬁed by Lerner 
in 1958. This hormone has a number of import- 
ant physiological functions including regula-
tion of circadian rhythms, sleep promotion and 
consolidation,1 anti-oxidative defense,2-4 immune 
regulation and aging,5,6 control of reproductive 
activity,7,8 and suppression of tumor growth.9,10
The secretion of melatonin is greatest during 
the dark hours of the night, an effect so con-
sistently expressed that it is now considered to 
be the chemical signal indicating the length of 
darkness.11 As the highest levels of melatonin 
secretion occur during the nighttime in diur-
nally active vertebrates, it has been suggested 
that melatonin has a crucial role in sleep promo-
tion, at least in this group of organisms. Owing 
to its involvement in the regulation of circadian 
rhythms, any disruption in melatonin secretion 
may play an important part in the etiology of 
circadian rhythm sleep disorders (CRSD). This 
has consequently led to advocacy for exogenous 
melatonin use in the treatment of CRSD.12-16 
Melatonin is also being widely used as a natural 
supplement or, in its analog variants, as a drug 
for various sleep disorders, including the (self-)
treatment of insomnia.17-20
MANAGEMENT OF INSOMNIA
Insomnia is one of the most frequently 
reported complaints in clinical practice 
and affects 30%-40% of the adult popula-
tion.21 It most commonly occurs in elderly 
individuals,22,23 in patients with depression,24 
and in those with dementia and neurodegen-
erative disorders. According to a National Sleep 
Foundation survey (USA), 75% of the adults in 
the USA have at least one symptom of a sleep 
disorder and 54% have one symptom related 
to insomnia.25 Treatment for insomnia includes 
both nonpharmacologic and pharmacologic 
treatments. Selection of an appropriate anti-
insomnia therapy is based upon a number of 
factors such as age, the nature of the disease, 
response to current medications, etc. A num-
ber of nonpharmacologic therapies includ-
ing cognitive behavioral therapy, relaxation 
therapy, yoga, stimulus control therapy, and 
sleep-hygiene education have all been employed 
for treatment of insomnia and have been vari-
ously found effective in certain cases.26,27 Drugs 
such as triazolam or zolpidem that act as benzo- 
diazepine receptor agonists (BzRAs) and that 
modulate gamma-aminobutyric A (GABAA) 
receptor function in the brain are used widely for 
treating insomnia.28 The antidepressant trazo- 
done is also commonly prescribed for the con-
dition. These drugs, however, have been linked 
to a number of side effects.
Benzodiazepines (BZDs) are associated with 
cognitive and memory impairment,29 while 
trazodone has been shown to cause cardiac 
rhythm disturbances and orthostatic hypoten-
sion.30 Drugs without these side effects would 
certainly benefit not only elderly individ- 
uals with insomnia but also a number of other 
patients with this condition.
Melatonin in Insomnia
Sleep disturbances, which are frequently 
observed in the elderly, have been related to 
low nocturnal melatonin production that is 
seen in most individuals of advanced age.31 
Melatonin’s sleep-promoting activity has 
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indeed been demonstrated both in animals 
and humans. Melatonin has been shown to 
reduce sleep onset latency (SOL) and to increase 
sleep efficiency when administered in the 
evening to healthy adults in doses ranging from 
0.3 to 1 mg.32,33 Brain imaging studies of awake 
subjects have shown that melatonin modu-
lates brain activity patterns to resemble those 
of actual sleep.34 A number of double-blind, 
placebo-controlled studies have demonstrated 
that melatonin is suitable as a hypnotic drug. 
In a study undertaken with 13 patients, rang-
ing in age from 25 to 65 years, administration 
of 75 mg of melatonin for 7 days signiﬁcantly 
increased the subjective report of total sleep 
time (TST) and daytime alertness when com-
pared with placebo;35 however, the dose of 
melatonin administered was high. In another 
study, a low dosage of melatonin was used. In 
this double-blind placebo-controlled study of 
10 patients, administration of melatonin in 
1 mg and 5 mg doses signiﬁcantly improved the 
overall subjective quality of sleep and promoted 
an earlier onset of sleep. Rapid eye movement 
onset latency was also delayed in this study.36
Melatonin administration (5 mg/fast-release 
tablets) was found to improve sleep quality in 
seven of 15 patients with insomnia who had 
been resistant to treatment with BZDs and zopi-
clone.37 In two separate groups of elderly patients 
with insomnia (mean age 73.1±5.2 years, eight 
patients; and 81.1±8.9 years, 18 patients), 
administration of 2 mg fast-release melatonin 
improved sleep efﬁciency (P<0.05).38 Similarly, 
in a randomized, double-blind, placebo- 
controlled crossover study of 12 elderly individ-
uals with chronic insomnia (aged 76±3.9 years), 
administration of 2 mg prolonged-release 
melatonin for 3 weeks followed by placebo 
resulted in signiﬁcant improvement of sleep 
efficiency (P<0.001)39 (This formulation has 
just been approved for the treatment of elderly 
individuals with insomnia by the European 
Medicines Agency [EMEA].) In one study the 
efﬁcacy of melatonin on sleep was evaluated 
in 25 patients (mean age 37.3±15.3 years) who 
had delayed sleep phase syndrome (DSPS). 
Polysomnography (PSG) revealed that mela-
tonin in 5 mg doses signiﬁcantly improved sleep 
quality without altering sleep architecture.40 In 
PSG studies of 20 patients with DSPS, mela-
tonin in doses of 5 mg/day for 4 weeks signiﬁ-
cantly decreased sleep latency when compared 
with placebo.41 Although in general published 
studies have employed only small numbers of 
patients, a meta-analysis of 17 studies clearly 
indicated that melatonin preparations pro-
duced statistically signiﬁcant beneﬁts in SOL, 
sleep efﬁciency, and sleep duration.42
Melatonin in the Regulation of Sleep: 
Possible Mechanisms of Action
Melatonin’s hypnotic and chronobiotic 
effects are believed to be primarily exerted via 
MT1 and MT2 receptors located in the circadian 
pacemaker, the suprachiasmatic nucleus (SCN) 
of the anterior hypothalamus.43-45 SCN neurons 
express high concentrations of both melatonin 
receptors, although both receptors are also found 
widely in the central nervous system. While the 
principal MT2-mediated actions in the SCN are 
related to circadian phase shifts and comprise 
activations of protein kinase C46,47 (an index of 
increased cell activity), signaling via MT1 leads 
primarily to suppression of the electrical activ-
ity of SCN neurons.48,49 It is, therefore, likely 
that the hypnotic effects of melatonin that are 
not associated with phase shifting are mediated 
by MT1. The role of SCN in the control of sleep 
has been well studied in various species. It is, 
however, important to make a clear distinction 
between sleep induction as well as maintenance 
of sleep at appropriate circadian phases and 
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phase shifting. In squirrel monkeys, a diurnal 
species like humans, the circadian signal pro-
duced by the SCN promotes wakefulness dur-
ing subjective day and consolidation of sleep at 
night. SCN lesions have been found to disrupt 
the consolidation of the sleep-wake cycle.50 The 
circadian rhythm of melatonin secretion also 
regulates core body temperature, a function 
that is known to inﬂuence sleep.1,51
Melatonin’s hypnotic effect has been shown 
to depend on the circadian phase of adminis-
tration. As shown by Stone et al.52 in a double- 
blind, placebo-controlled study, melatonin 
administered at night (11:30 PM) had no sig-
niﬁcant effect on nighttime sleep in healthy 
individuals, whereas its administration in the 
evening (6:00 PM) exerted hypnotic activity. 
Although the exact reason for this difference 
is not known, melatonin levels in the cerebro-
spinal ﬂuid of the third ventricle, which are 
nearly 20 times higher than those found in 
the circulation, were assumed to be responsible 
for the variations of melatonin’s action in the 
brain.53,54 Despite the evidence of these cited 
reports on melatonin’s hypnotic actions, its 
efﬁcacy in promoting sleep efﬁciency has been 
questioned, especially as most of the results 
have shown only borderline signiﬁcance or are 
otherwise difﬁcult to evaluate because of meth-
odological inconsistencies.55 The poor out-
comes concerning sleep efﬁciency or TST have 
been attributed to melatonin’s short half-life 
(of less than 30 minutes) in the circulation. It 
has therefore been suggested that a melatoner-
gic agonist with a longer half-life and, thus, an 
enhanced bioavailability, would saturate MT1 
and MT2 receptors in the SCN more efﬁciently 
and for a longer duration of time. It has con-
sequently been further suggested that such an 
agonist might be of greater beneﬁt than mela-
tonin in promoting sleep efﬁciency in patients 
with insomnia.54
RAMELTON, A MELATONERGIC 




TAK-375} is a novel melatonin receptor ago-
nist that has been shown to be selective for MT1 
and MT2 receptors, but without afﬁnity for the 
melatonin-binding quinone reductase 2, previ-
ously called MT3.56,57 Ramelteon has no afﬁnity 
for GABA-ergic, dopaminergic, opioidergic, nor 
any other major CNS receptors, binding sites of 
neurotransmitters or neuropeptides, regulatory 
enzymes, or ion channels.56,57 However, various 
additional nonmembrane-binding sites of mela-
tonin remain to be tested.58
Pharmacokinetics of Ramelteon
In-vitro binding studies have shown that 
ramelteon’s afﬁnity for MT1 and MT2 receptors 
is 3-16 times higher than that of melatonin 
itself. Although ramelteon has a relatively short 
half-life (1.2 hours), it is, however, substan-
tially longer than that of melatonin.56 When 
administered orally, ramelteon is absorbed 
rapidly in fasting conditions and reaches its 
peak concentration in plasma in 45 minutes, 
which ranges from 30 minutes to 1.5 hours. 
The total absorption of this drug is 84%, but 
its total bioavailability is only 1.8%. After 
administration of the therapeutic dose (8 mg), 
the peak plasma concentration of ramelteon 
increases up to 57,000 pg/mL.59
Ramelteon is metabolized by oxidation to 
hydroxyl and carbonyl derivatives and is elimi-
nated within 96 hours after oral administration. 
It is metabolized in humans to four metabolites: 
M-I, M-II, M-III, and M-IV. M-II is the major 
metabolite of ramelteon followed by M-IV, 
M-I, and M-III. M-II exhibits a selectivity for 
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melatonin MT1 and MT2 receptors that is similar 
to that of the parent compound; however, it has 
an afﬁnity of only 10% of that of ramelteon.56 
M-II attains plasma concentrations 20-100-fold 
(average about 30-fold) greater than that of the 
parent compound,60 M-II, which is formed by 
the cytochrome P450 subform CYP1A2, and has 
a half-life of 2-4 hours in the circulation, a value 
that only partially explains the differences in 
concentration. Despite the lower receptor afﬁn-
ity, the considerably higher blood levels of M-II 
support the hypothesis that this metabolite 
should substantially contribute to ramelteon’s 
overall activity,60 and may enhance its sleep-
promoting efficacy. Ramelteon clearance has 
often been shown to be signiﬁcantly reduced in 
elderly subjects, an effect that is not signiﬁcantly 
inﬂuenced by gender. In view of the extended 
persistence of M-II in the circulation, the phar-
macokinetics of the drug should not be primar-
ily judged on the basis of ramelteon clearance 
alone. This is one of the most unusual pharma-
cokinetic properties of ramelteon.
Ramelteon: Sleep-Promoting Actions in 
Primate Studies
In a study conducted in young adult female 
monkeys (n=22) (Macaca fascicularis), cortical 
electroencephalography, electromyography, and 
electrooculography were recorded.61 Individual 
monkeys received, at 6:00 PM, different doses 
of ramelteon (0.003, 0.03, and 0.3 mg/kg) and, 
correspondingly, other animals were treated at 
the same circadian phase with different doses of 
melatonin (0.3, 1, and 3 mg/kg). For comparison, 
zolpidem was also administered to other experi- 
mental groups (1, 3, 10, and 30 mg/kg). The 
study demonstrated that ramelteon, in doses of 
0.03 and 0.3 mg/kg, was effective in reducing the 
time to sleep onset as compared with controls. 
Ramelteon, in these two doses, also signiﬁcantly 
increased the total duration of sleep. Melatonin 
(1 and 3 mg doses) also tended to increase the 
total duration of sleep, but without attain-
ing statistical signiﬁcance. Zolpidem, in none 
of the doses tested (1, 3, 10, and 30 mg/kg), 
had any effect on the latency to slow wave 
sleep, nor on TST. The investigators concluded 
that ramelteon reduced the SOL and increased 
sleep duration in freely moving monkeys with-
out producing the side effects often seen with 
BzRAs.61 In another study in monkeys, ramel- 
teon did not promote physical dependence,62 a 
ﬁnding of particular importance for judging the 
usefulness of the drug.
Ramelteon’s Effects on Sleep: Clinical Studies
The efficacy, safety, and dose-response of 
ramelteon were evaluated by Erman et al.63 in 
a multicenter clinical trial. One hundred and 
seventeen patients with chronic primary insom-
nia were studied in 13 centers in a double-blind, 
randomized, crossover investigation, which took 
place over a 5-year period. The mean age of the 
enrolled patients was 37.7 years. Each patient 
was randomized to a dose sequence of 4, 8, 16, 
and 32 mg ramelteon or placebo. Each patient 
underwent ﬁve 2-day treatment periods. The 
investigators found that all doses of ramelteon 
resulted in statistically signiﬁcant reductions in 
latency to persistent sleep (LPS) and increased 
sleep duration, as measured by PSG.63 Further, it 
was noted that ramelteon did not produce any 
residual sedation, nor psychomotor nor mem-
ory impairment. Of the 117 patients studied, 
103 completed the study. The reasons given for 
premature withdrawal were not directly related 
to drug use. In the subjects that completed 
the study, all doses of ramelteon (4, 8, 16, and 
32 mg) resulted in statistically signiﬁcant reduc-
tions in LPS (P<0.001) and increases in TST 
(P<0.05). Patients with a higher LPS at screening 
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(>66.5 minutes) experienced more reductions 
in the time to reach persistent sleep. Mean LPS 
was 26.2-29.8 minutes across treatment groups 
as compared with 48.8 minutes for placebo 
(P<0.001). In contrast, in patients with a shorter 
screening LPS (<66.5 minutes) the LPS was 15.7-
21.8 minutes across treatment groups as com-
pared with 26.2 minutes for placebo (P<0.05). 
Similarly, the group of patients with a screen-
ing TST less than 358 minutes showed greater 
improvements than did the group whose screen-
ing was greater than 358 minutes.63 All ramelt-
eon doses resulted in similar improvements 
suggesting that ramelteon promotes sleep in a 
manner that differs from that of other hypnotics. 
More speciﬁcally, ramelteon activates MT1 recep-
tors in the SCN to attenuate the circadian wake-
promoting signal, thus allowing the homeostatic 
sleep load to promote sleep.63
Roth et al.64 investigated the subjective efﬁ-
cacy of ramelteon in 829 elderly outpatients 
(mean age of 72.4 years) with chronic insomnia. 
Of the initially selected sample, 128 patients were 
discontinued. In a double-blind study ramel- 
teon was administered in doses of 4 or 8 mg/day 
for a period of 5 weeks in comparison with pla-
cebo. Discontinuation was approximately equal 
between groups being due most commonly 
to a lack of efﬁcacy (placebo, n=17; ramelteon 
4 mg, n=14; and ramelteon 8 mg, n=9), proto-
col deviation (placebo, n=10; ramelteon 4 mg, 
n=15; and ramelteon 8 mg, n=10), and adverse 
events (placebo, n=8; ramelteon 4 mg, n=8; and 
ramelteon 8 mg, n=7). Compared with the pla-
cebo group, patients in both ramelteon groups 
reported statistically signiﬁcant reductions in 
SOL (16%-35%) at the end of week 1 and week 5. 
Also, in this study a greater treatment effect was 
found in patients who had a high baseline sleep 
latency (>67.1 minutes). The overall median of 
baseline sleep latency (>67.1 minutes) was used 
as the cut-off value. The superiority of ramelteon 
over placebo in reducing sleep latency was con-
sistently demonstrated at every dose level and 
time period that were evaluated:
At week 1—for 4 mg: 93.1 minutes with ramel- s 
teon vs. 107.0 minutes with placebo 
(P=0.013); for 8 mg: 90.2 vs. 107.0 minutes 
(P=0.003).
At week 3—for 8 mg: 79.3 vs. 96.5 minutes s 
(P=0.004).
At week 5—for 4 mg: 83.6 vs. 98.2 minutes s 
(P=0.015); for 8 mg: 74.9 vs. 98.2 minutes 
(P<0.001).
Increases in TST were observed in both ramel- 
teon groups at week 1 (P=0.004) and week 3 
(P=0.055). At week 1, for 4 mg of ramelteon the 
effect was 324.6 vs. 313.9 minutes with placebo 
(P=0.004); for 8 mg: 321.1 vs. 313.9 min- 
utes (P=0.055). At week 3, for 4 mg of ramel- 
teon the effect was 336.0 vs. 324.3 minutes 
(P=0.007); for 8 mg: 332.1 vs. 324.3 minutes 
(P=0.071). These results were consistent with 
patient reports of enhanced sleep quality and of 
feeling refreshed upon arising in the morning — 
ﬁndings also in agreement with PSG studies on 
ramelteon.65 Sleep promotion by ramelteon was 
dose-independent as in a previous study.65 This 
study also supports the ﬁnding that ramelteon 
is a chronohypnotic agent with a speciﬁc action 
on MT1 and MT2 receptors in the SCN that are 
involved in the normal regulation of a sleep-
wake cycle.
In a clinical study on 100 elderly patients 
drawn from 17 sleep centers, ramelteon in doses 
of 4 mg/day increased patients’ TST (P=0.036) 
and sleep efﬁciency (P=0.037) and shortened the 
LPS (P=0.001).65
The effects of differing doses of ramelteon 
were studied by Zammit and coworkers66 in 
another multicenter, double-blind, placebo- 
controlled study. The investigators used PSG to 
evaluate the effects of ramelteon 8 mg and 16 mg 
on 405 patients with chronic insomnia. A total of 
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371 patients completed the double-blind study 
and 267 completed the single-blind follow-up. 
During the double-blind treatment period dis-
continuation was due to adverse events (n=6), 
lack of efficacy (n=2), protocol deviation 
(n=6), withdrawal of consent (n=18), lost to 
follow-up (n=1), and withdrawn because of 
noncompliance (n=1). During a single-blind 
runout period after treatment four subjects 
were lost: discontinued treatment due to 
adverse event (n=1), withdrawal of consent 
(n=1), protocol deviation (n=1), and one sub-
ject missed visit 5 due to work-related travel. 
LPS was signiﬁcantly reduced with ramelteon 
8 mg (32.2 minutes) or 16 mg (28.9 minutes), 
when compared with placebo (47.9 min-
utes). These effects were maintained following 
3-5 weeks (after ramelteon was discontinued). 
Both doses of ramelteon also prolonged total 
duration of sleep.66
In a related study involving a larger popu-
lation (289 adults), the efﬁcacy and safety of 
ramelteon, 8 mg and 16 mg per day, was eval-
uated.67 Compared with placebo, ramelteon at 
8 mg signiﬁcantly reduced PSG measures of LPS 
(12.2-19.7 minutes, P=0.004). TST was signiﬁ-
cantly increased by ramelteon at both 8 mg/day 
(436.8 minutes, P=0.009) and 16 mg/day 
(433.1 minutes, P=0.043).67 In another 5-week, 
double-blind, controlled study carried out 
by Takeda Pharmaceuticals, Illinois, USA, the 
effects of 8 mg/day doses of ramelteon were 
evaluated in 270 patients with chronic insom-
nia.68 Ramelteon 8 mg/day was associated with 
reductions in LPS at week 1 (63% for ramelteon 
vs. 39.7% for placebo; P<0.001), week 3 (ramel- 
teon 63% vs. placebo 41.2%; P<0.01), and 
week 5 (ramelteon 65.9% vs. placebo 48.9%; 
P<0.05). The improvement in LPS, which was 
evident from the ﬁrst week, was sustained until 
week 5, without associated withdrawal effects or 
rebound insomnia.68
In a longitudinal study ramelteon 8 mg/day 
improved sleep in the ﬁrst week, but was associ-
ated with somewhat mixed effects at later stages 
of the study. The drug was nevertheless well tol-
erated by the sample with chronic insomnia.69
A recently published pooled analysis included 
four randomized, double-blind, placebo- 
controlled clinical trials of ramelteon in 
566 adult patients with chronic insomnia 
who took ramelteon 8 mg as compared with 
556 patients with insomnia who took pla- 
cebo.70 Ramelteon reduced LPS on nights 1 and 2 
by 13 minutes more than placebo in adults with 
chronic insomnia. At nights 1 and 2 the mean 
LPS for the ramelteon 8 mg group was 30.2 min- 
utes, which was significantly less than the 
mean LPS for the placebo group at 43.3 minutes 
(P<0.01), thus substantiating the clinical efﬁcacy 
of ramelteon in promoting sleep.
The effectiveness and tolerability of ramel- 
teon was also examined in adult patients 
with generalized anxiety disorder and insom-
nia symptoms in an open-label study, includ-
ing 27 adults with sleep disturbance meeting 
DSM-IV diagnostic criteria.71 After 12 weeks a 
signiﬁcant symptom reduction was observed on 
all scales, with patients falling asleep faster and 
sleeping longer; the data suggesting that ramel- 
teon may be an effective treatment for insomnia 
symptoms in generalized anxiety disorder.
In a 6-month randomized, double-blind, 
placebo-controlled study carried out in 46 cen-
ters in the USA, Europe, Russia, and Australia, 
451 adults (age ≥18 years) with chronic pri-
mary insomnia received ramelteon 8 mg or 
placebo 30 minutes before bedtime.72 Sleep 
was evaluated by PSG and morning question-
naires on the first 2 nights of week 1; the 
last 2 nights of months 1, 3, 5, and 6; and 
nights 1 and 2 of the placebo run-out. Over 
the 6 months of treatment, ramelteon con-
sistently reduced LPS compared with baseline 
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and with placebo with no significant next 
morning residual effects, withdrawal symp-
toms, or rebound insomnia.
Sleep disturbances have been reported to 
be one of the most troubling manifestations 
of menopause.21 In 20 healthy peri- and post-
menopausal women with insomnia participat-
ing in a 6-week, prospective, open-label trial of 
ramelteon (8 mg), signiﬁcant improvements in 
SOL, TST, and sleep efﬁciency were observed 
in diary data while gains in sleep quality, sleep 
impairment, daytime functioning, quality of 
life, and mood were found in self-report mea-
sures.73 There was no evidence of tolerance nor 
rebound insomnia over the course of the trial. 
Randomized controlled trials are needed to fur-
ther evaluate the efﬁcacy of ramelteon’s use by 
menopausal women. This recommendation is 
particularly relevant as many women are now 
seeking alternative treatments for sleep disturb- 
ances in menopause due to concerns about the 
risks and side effects of the commonly employed 
hormone replacement treatments.
DSPS is a CRSD in which SOL is delayed in 
some cases by as much as 2-6 hours. It is char-
acterized by the chronic inability to fall asleep 
at the desired clock time.74 Dahlitz et al.75 
reported that the administration of 5 mg mela-
tonin advanced sleep onset time by an aver-
age of 82 minutes (range 19-124 minutes) and 
waking time by 117 minutes in patients with 
DSPS. There is evidence to implicate endo- 
genous melatonin as an important factor in the 
pathophysiology of CRSD.16 The therapeutic 
potential of ramelteon to treat CRSD was indi-
cated by a study of the phase-shifting capacity 
of varying doses of the compound in healthy 
subjects.76 Ramelteon, at doses of 1, 2, 4, and 
8 mg, was administered to 75 adults of the age 
group 18-45 years for 6 days. Administration 
of 1, 2, or 4 mg of ramelteon for a period of 
4 days was found to promote signiﬁcant phase 
advance shifts, assessed by determining the dim 
light melatonin offset effect (“DLMoff”), ie, the 
time point when salivary melatonin dropped to 
below 3 pg/mL (normally after morning awak-
ening). Shifts of –7.1±18.6, –88±16.6 (P=0.002), 
–80.5±14.8 (P=0.003), and –90.5±15.2 minutes 
were determined for placebo, 1, 2, and 4 mg, 
respectively (P=0.001 for significance ramel- 
teon vs. placebo). Surprisingly, the higher dose 
of 8 mg ramelteon/day did not cause any sig-
nificant changes as compared with placebo 
(–27.9±16.4 minutes, P=0.392) — an unexpected 
divergence between the soporiﬁc and phase shift-
ing effects according to DLMoff. Although this 
discrepancy was not resolved, it was concluded 
that ramelteon nevertheless had the thera- 
peutic potential for treating CRSD.76
ADVERSE EFFECTS OF RAMELTEON 
AND SAFETY
The incidence of adverse effects of ramelteon, 
as inferred from subjects’ complaints and neuro-
logic parameters, has been reported to be similar 
to that of placebo. In a study by Erman et al.63 
the incidence of treatment-emergent adverse 
events ranged from 8.4% to 10.7% among the 
ramelteon groups and was 8.7% in the placebo 
group. The most commonly reported adverse 
events were headache, somnolence, dizziness, 
and sore throat. Ramelteon was found to be well 
tolerated and showed no signiﬁcant next-day 
morning psychomotor, memory, or cognitive 
effects.67,77,78 Inasmuch as all currently available 
BZDs and non-BZD hypnotics cause either addic-
tion, withdrawal symptoms, or trigger rebound 
insomnia, the relative absence of symptoms fol-
lowing the use of ramelteon underscores its spe-
ciﬁc advantages for the treatment of insomnia.
In an open-label study, patients with pri-
mary insomnia received ramelteon nightly for 
1 year.79 Subjects aged ≥65 years received ramel- 
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teon, 8 mg (n=248), while those aged 18-64 years 
received ramelteon, 16 mg (n=965). Ramelteon 
was associated with sustained improvements 
in subjective sleep latency, subjective TST, and 
Clinical Global Impressions. A total of 495 
of 1213 subjects (40.8%) reported at least one 
adverse event possibly associated with ramel- 
teon use. The adverse events reported varied 
considerably (mild=30.7%; moderate=54.2%; 
and severe=15.1%), the incidence of individual 
adverse events was low (12.2% discontinued 
due to adverse events), and the frequencies of 
adverse events were similar at months 6 and 12 
for both age groups. There were no noteworthy 
changes in vital signs, physical examinations, 
clinical chemistry, hematology, or urinalysis val-
ues and no electrocardiogram changes to sug-
gest adverse cardiac effects. Endocrine values 
remained within normal range throughout treat-
ment although consistent statistically signiﬁ-
cant decreases in free thyroxine (in adults) and 
free testosterone (in older men) were detected. 
Duration of menses increased by approximately 
1 day.79
In a double-blind, placebo-controlled trial of 
adults (18-45 years) with chronic insomnia to 
evaluate the effects of ramelteon on endocrine 
function ramelteon 16 mg or placebo was given 
nightly for 6 months.77 There were no consis-
tent statistically signiﬁcant differences between 
treatments on measures of thyroid function 
(total or free thyroxine, thyroid-stimulating hor-
mone, total triiodothyronine), adrenal function 
(morning cortisol and adrenocorticotropic hor-
mone), or on most reproductive endocrine mea-
sures (luteinizing hormone, follicle-stimulating 
hormone, estradiol [women], total and free 
testosterone [men]). Prolactin concentrations 
were increased overall in women in the ramel- 
teon group compared with placebo (P=0.003). 
No clinical effects of elevated prolactin were 
reported; average menstrual cycle length, 
duration of menses, and ovulation probability 
did not differ between groups.77
Objective criteria in relation to metabolism, 
other diseases, hepatotoxicity, etc, have been 
also investigated by Takeda Pharmaceuticals, 
and ramelteon clearly met a number of such 
safety requirements that had been funda-
mental for approval by the Food and Drug 
Administration (FDA). Nevertheless, it should 
not be overlooked that the melatonin recep-
tors MT1 and MT2 are not only located in the 
SCN and do not only regulate the circadian 
pacemaker. Additional effects via these recep-
tors have to be expected, eg, in cerebral vaso- 
motor control, in immunomodulation, and 
other hormonal systems, including those 
involved in reproduction. Reasons for concern in 
this regard have been discussed elsewhere58,80,81 
and may become particularly relevant for long-
term treatment with the drug.
It should be noted that in May 2008 the 
EMEA declined to grant marketing authori-
zation for ramel-teon. Following this, Takeda 
Pharmaceuticals requested a re-examination of 
the opinion, which was under review at the time 
of the application withdrawal by the company, 
based on its current plan to extend the clinical 
program to address EMEA’s questions regarding 
the medicine’s risk-beneﬁt proﬁle.
Some Pharmacodynamic Considerations 
Concerning Ramelteon
Taken together, the evidence reviewed above 
suggests generally that ramelteon, like mela-
tonin, exerts its direct sleep-inducing effects via 
MT1 receptors located in the SCN, while inducing 
phase shifting, mainly via MT2 receptors. Because 
ramelteon’s direct soporiﬁc effect, as measured 
by the reduction of SOL (but not the phase- 
shifting capacity) is indistinguishable at 4 mg 
and 8 mg, ramelteon seems to promote sleep by 
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regulating the sleep-wake cycle rather than hav-
ing a more generalized CNS depressant effect. 
This is supported by observations that ramelteon 
does not worsen sleep apnea in insomniacs.82
Owing to its potent effect on melatonin 
receptors in the SCN, ramelteon should accel-
erate sleep onset by inﬂuencing the hypotha-
lamic “sleep-switch” downstream from the 
SCN, in principle in the same way as melatonin. 
However, owing to its higher receptor afﬁnity 
it does so more efﬁciently.58 The sleep-switch 
model originally proposed by Saper and col-
leagues82 describes “ﬂip-ﬂop” reciprocal inhibi-
tions among sleep-associated activities in the 
ventrolateral preoptic nucleus and wakefulness 
associated activities in the locus coeruleus, dor-
sal raphe, and tuberomammilary nuclei.83,84 It 
has been hypothesized that the prolonged use 
of ramelteon can result in the desensitization 
of MT2 receptors in the SCN.85 However, no evi-
dence for such an effect has been provided for 
ramelteon. From studies of the SCN or immort- 
alized SCN2.2 neurons desensitization and 
internalization of MT2 is known to occur follow-
ing exogenous melatonin administration.86,87 
Whether or not downregulation by ramelteon 
is stronger or longer-lasting, or even occurs, 
remains to be demonstrated.
In any event, the studies of ramelteon’s 
actions indicate that this drug, the ﬁrst mela-
tonin receptor agonist approved by the FDA, 
represents a good pharmacologic option for the 
treatment of sleep initiation in insomnia88 and 
thus has a promising future for use in patients 
with chronic insomnia.58
CONCLUSIONS
Ramelteon has been reported to be a safe 
hypnotic drug for clinical use in chronic pri-
mary insomnia. Clinical studies have shown 
that ramelteon reduces the SOL and increases 
TST. During treatments lasting several weeks, the 
incidence of adverse effects with ramelteon has 
been reported to be similar to that of placebo. 
Ramelteon administration has been shown to 
be free of other undesired effects such as next 
day hangover, memory impairment, psycho- 
motor retardation, or cognitive impairment. The 
hypnotic action of ramelteon is attributed to its 
effect on melatonergic MT1 and MT2 receptors 
present in the SCN. It has been also effective in 
causing phase advances of sleep-wake rhythms 
in humans, and thus has potential therapeutic 
value not only in primary insomnia but also in 
CRSD. No study is available comparing ramel- 
teon versus melatonin in their efﬁcacy.
Other melatonergic agonists, such as agomela- 
tine and tasimelteon, are now on the market or 
are in the process of being approved by the FDA 
or EMEA. Moreover, a slow-release preparation 
of melatonin has just been approved by EMEA 
for use in elderly patients with sleep disorders. 
A last important point to be considered is that 
melatonin-like compounds generally display a 
modest sleep-inducing effect, quite mild as com-
pared with BZP. Certainly because of the long 
time in the market and the lack of new alterna-
tives for the treatment of insomnia, the precon-
ception that the consumer has of a sleep pill is 
that of a strong sleep inducer, something that 
the melatonin family of compounds will never 
accomplish. Therefore, a very important educa-
tional goal is to change this view on the lack 
of negative effects (addiction, dependence, etc) 
that melatonin analogs have in the face of the 
well-known complications of BZP.89
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